These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29582525)

  • 1. Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies.
    Rusen L; Kavakli K; Korth-Bradley J; Huard F; Rendo P; Fuiman J; Baumann JA; Smith L; Alvey C; Rupon J
    Haemophilia; 2018 Jul; 24(4):604-610. PubMed ID: 29582525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
    Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
    Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A.
    Liu H; Wu R; Hu P; Sun F; Xu L; Liang Y; Nepal S; Qu PR; Huard F; Korth-Bradley JM
    Clin Ther; 2017 Jul; 39(7):1313-1319. PubMed ID: 28601434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom.
    Mathias MC; Collins PW; Palmer BP; Chalmers E; Alamelu J; Richards M; Will A; Hay CRM;
    Haemophilia; 2018 Nov; 24(6):896-901. PubMed ID: 30004617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
    Kulkarni R; Karim FA; Glamocanin S; Janic D; Vdovin V; Ozelo M; Rageliene L; Carboni E; Laguna P; Dobaczewski G; Seremetis S; Lindblom A; Santagostino E
    Haemophilia; 2013 Sep; 19(5):698-705. PubMed ID: 23651313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies.
    Yang R; Zhao Y; Wang X; Sun J; Wu R; Jin C; Jin J; Wu D; Rendo P; Sun F; Rupon J; Huard F; Korth-Bradley JM; Xu L; Luo B; Liu YC
    J Blood Med; 2020; 11():439-448. PubMed ID: 33269010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
    Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
    Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
    Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
    Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PROTECT VIII kids extension study: Long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A.
    Mancuso ME; Biss T; Fischer K; Maas Enriquez M; Steele M; Wang M; Tseneklidou-Stoeter D; Ahuja S; Kenet G
    Haemophilia; 2021 May; 27(3):434-444. PubMed ID: 33724632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.
    Mullins ES; Stasyshyn O; Alvarez-Román MT; Osman D; Liesner R; Engl W; Sharkhawy M; Abbuehl BE
    Haemophilia; 2017 Mar; 23(2):238-246. PubMed ID: 27891721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of treatment regimen with moroctocog alfa (AF-CC) on bleeding rates in paediatric patients with severe haemophilia A.
    Smith MP; Rupon J; Wali Y; Rimawi H; Korth-Bradley J; Smith L; Rendo P
    Haemophilia; 2020 Sep; 26(5):e232-e235. PubMed ID: 32497363
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.
    Yaish H; Matsushita T; Belhani M; Jiménez-Yuste V; Kavakli K; Korsholm L; Matytsina I; Philipp C; Reichwald K; Wu R
    Haemophilia; 2020 Jan; 26(1):64-72. PubMed ID: 31816159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A.
    Wu R; Wang X; Zhao X; Cheng Y; Zhou Z; Sun J; Xu M; Li W; Xiao J; Yang F; Chen Y; Xu W; Huang J; Ma C; Gai W; Xie L; Yang R
    Haemophilia; 2022 Nov; 28(6):e199-e208. PubMed ID: 35802040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII.
    Recht M; Nemes L; Matysiak M; Manco-Johnson M; Lusher J; Smith M; Mannucci P; Hay C; Abshire T; O'Brien A; Hayward B; Udata C; Roth DA; Arkin S
    Haemophilia; 2009 Jul; 15(4):869-80. PubMed ID: 19473411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
    Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune tolerance induction with moroctocog-alpha (Refacto/Refacto AF) in a population of Italian haemophilia A patients with high-titre inhibitors: Data from REF.IT Registry.
    Zanon E; Pasca S; Pollio B; Santagostino E; Linari S; Tagliaferri A; Santoro C; Rocino A; Marino R; Aru B; Borchiellini A; Siragusa S; Coppola A
    Haemophilia; 2019 Nov; 25(6):1003-1010. PubMed ID: 31603594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
    Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
    Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
    Lentz SR; Misgav M; Ozelo M; Salek SZ; Veljkovic D; Recht M; Cerqueira M; Tiede A; Brand B; Mancuso ME; Seremetis S; Lindblom A; Martinowitz U
    Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.
    Smith MP; Giangrande P; Pollman H; Littlewood R; Kollmer C; Feingold J;
    Haemophilia; 2005 Sep; 11(5):444-51. PubMed ID: 16128886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF-CC) in Subjects With Severe Hemophilia A.
    Korth-Bradley J; Rupon J; Plotka A; Charnigo R; Rendo P
    Clin Transl Sci; 2018 May; 11(3):283-288. PubMed ID: 29575770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.